Einat Almon

653 total citations
23 papers, 527 citations indexed

About

Einat Almon is a scholar working on Physiology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Einat Almon has authored 23 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Physiology, 8 papers in Organic Chemistry and 7 papers in Molecular Biology. Recurrent topics in Einat Almon's work include Lysosomal Storage Disorders Research (9 papers), Carbohydrate Chemistry and Synthesis (8 papers) and Inflammatory Bowel Disease (4 papers). Einat Almon is often cited by papers focused on Lysosomal Storage Disorders Research (9 papers), Carbohydrate Chemistry and Synthesis (8 papers) and Inflammatory Bowel Disease (4 papers). Einat Almon collaborates with scholars based in Israel, United States and United Kingdom. Einat Almon's co-authors include Varda Rotter, Arnold J. Levine, Ahuva Kapon, Dov Schwartz, Naomi Goldfinger, L A Donehower, A. Meshorer, Raul Chertkoff, William J. Lucas and Sebastian Wolf and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and PLoS ONE.

In The Last Decade

Einat Almon

23 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Einat Almon Israel 11 298 137 103 96 81 23 527
J. L. Schwartz United States 16 357 1.2× 102 0.7× 63 0.6× 13 0.1× 34 0.4× 39 595
Tatiana Cajuso Finland 9 331 1.1× 134 1.0× 40 0.4× 27 0.3× 61 0.8× 10 489
Inger Brandsma Netherlands 14 466 1.6× 217 1.6× 93 0.9× 9 0.1× 69 0.9× 24 691
Mark J. Dycaico United States 11 546 1.8× 108 0.8× 91 0.9× 28 0.3× 187 2.3× 15 733
Dingqing Feng China 14 269 0.9× 104 0.8× 22 0.2× 13 0.1× 22 0.3× 37 484
Francesco Paolo Fiorentino Italy 13 346 1.2× 176 1.3× 17 0.2× 12 0.1× 27 0.3× 20 573
Theresa Allio United States 8 484 1.6× 266 1.9× 11 0.1× 28 0.3× 29 0.4× 8 614
Masako Mori Japan 12 236 0.8× 63 0.5× 15 0.1× 35 0.4× 51 0.6× 21 437
Esperanza Torres Spain 15 656 2.2× 101 0.7× 185 1.8× 488 5.1× 32 0.4× 30 884

Countries citing papers authored by Einat Almon

Since Specialization
Citations

This map shows the geographic impact of Einat Almon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Einat Almon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Einat Almon more than expected).

Fields of papers citing papers by Einat Almon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Einat Almon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Einat Almon. The network helps show where Einat Almon may publish in the future.

Co-authorship network of co-authors of Einat Almon

This figure shows the co-authorship network connecting the top 25 collaborators of Einat Almon. A scholar is included among the top collaborators of Einat Almon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Einat Almon. Einat Almon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Holida, Myrl, Aleš Linhart, Antonio Pisani, et al.. (2024). A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. Journal of Inherited Metabolic Disease. 48(1). e12795–e12795. 6 indexed citations
2.
Bernat, John, Derralynn Hughes, Aleš Linhart, et al.. (2024). Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies. Molecular Genetics and Metabolism. 141(2). 107771–107771. 1 indexed citations
3.
Hughes, Derralynn, Derlis Gonzalez, Gustavo Maegawa, et al.. (2023). Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease. Genetics in Medicine. 25(12). 100968–100968. 20 indexed citations
4.
Bernat, John, Myrl Holida, Nicola Longo, et al.. (2023). Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study. Molecular Genetics and Metabolism. 138(2). 107027–107027. 2 indexed citations
5.
Bernat, John, Myrl Holida, Nicola Longo, et al.. (2022). eP149: Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: Results from the phase 3, open-label, BRIGHT study. Genetics in Medicine. 24(3). S91–S92. 4 indexed citations
6.
Linhart, Aleš, Gabriela Dostálová, Kathy Nicholls, et al.. (2021). Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study. Molecular Genetics and Metabolism. 132(2). S65–S65. 1 indexed citations
7.
Almon, Einat, Yoseph Shaaltiel, Wisam Sbeit, et al.. (2020). Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis. Journal of Clinical Gastroenterology. 55(2). 134–140. 17 indexed citations
8.
Linhart, Aleš, Kathy Nicholls, Michael L. West, et al.. (2019). Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa. Molecular Genetics and Metabolism. 126(2). S94–S94. 4 indexed citations
9.
Holida, Myrl, John Bernat, Nicola Longo, et al.. (2019). Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease Preliminary results of a phase 3 study. Molecular Genetics and Metabolism. 126(2). S73–S73. 7 indexed citations
10.
11.
Rup, Bonita, Sari Alon, Einat Almon, et al.. (2017). Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story. PLoS ONE. 12(10). e0186211–e0186211. 39 indexed citations
12.
Almon, Einat, Tawfik Khoury, Svetlana Gingis‐Velitski, et al.. (2017). An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. Journal of Immunological Methods. 446. 21–29. 20 indexed citations
13.
14.
15.
16.
Zimran, Ari, Hanna Rosenbaum, Myriam Golembo, et al.. (2014). Oral administration of glucocerebrosidase for the treatment of Gaucher disease: a completely new approach. Molecular Genetics and Metabolism. 111(2). S117–S118. 1 indexed citations
17.
18.
Reisman, David, Éva Bálint, William Loging, Varda Rotter, & Einat Almon. (1996). A Novel Transcript Encoded within the 10-kb First Intron of the Human p53 Tumor Suppressor Gene (D17S2179E) Is Induced during Differentiation of Myeloid Leukemia Cells. Genomics. 38(3). 364–370. 20 indexed citations
19.
Almon, Einat, N. Navot, A. Perl, et al.. (1996). Tissue-Specific Expression of the Tobacco Mosaic Virus Movement Protein in Transgenic Potato Plants Alters Plasmodesmal Function and Carbohydrate Partitioning. PLANT PHYSIOLOGY. 111(2). 541–550. 52 indexed citations
20.
Almon, Einat, Naomi Goldfinger, Ahuva Kapon, et al.. (1993). Testicular Tissue-Specific Expression of the p53 Suppressor Gene. Developmental Biology. 156(1). 107–116. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. L. Schwartz Breakdown of academic impact, for papers by Tatiana Cajuso Breakdown of academic impact, for papers by Inger Brandsma Breakdown of academic impact, for papers by Mark J. Dycaico Breakdown of academic impact, for papers by Dingqing Feng Breakdown of academic impact, for papers by Francesco Paolo Fiorentino Breakdown of academic impact, for papers by Theresa Allio Breakdown of academic impact, for papers by Masako Mori Breakdown of academic impact, for papers by Esperanza Torres
Rankless by CCL
2026